Welcome to STN International! Enter x:x

LOGINID:ssspta1600rxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 09	JAPIO to be reloaded August 25, 2002
NEWS 20	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 21	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 22	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

```
FILE 'HOME' ENTERED AT 12:38:17 ON 23 AUG 2002

=> fil reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:38:25 ON 23 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   21 AUG 2002  HIGHEST RN 444646-89-3
DICTIONARY FILE UPDATES:  21 AUG 2002  HIGHEST RN 444646-89-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10049904.str

L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 12:38:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     12 TO ITERATE

100.0% PROCESSED      12 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           33 TO      447
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
```

FULL SEARCH INITIATED 12:38:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 173 TO ITERATE

100.0% PROCESSED 173 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

L3 13 SEA SSS FUL L1

=> d scan

L3 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]- (9CI)
MF C26 H24 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(3-methoxyphenoxy)phenyl]methyl]- (9CI)
MF C26 H24 N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]- (9CI)
MF C26 H24 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	140.28	140.49

FILE 'CAPLUS' ENTERED AT 12:39:15 ON 23 AUG 2002

FILE COVERS 1907 - 23 Aug 2002 VOL 137 ISS 8
FILE LAST UPDATED: 21 Aug 2002 (20020821/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l3
L4 1 L3

=> d ibib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:152660 CAPLUS
DOCUMENT NUMBER: 134:193427
TITLE: Preparation of substituted benzylthiazolidine-2,4-dione derivatives as agonists of human peroxisome proliferator-activated receptor
INVENTOR(S): Miyachi, Hiroyuki; Nomura, Masahiro; Tanase, Takahiro; Murakami, Koji; Tsunoda, Masaki
PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014351	A1	20010301	WO 2000-JP5521	20000818
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1207157	A1	20020522	EP 2000-953477	20000818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: JP 1999-235529 A 19990823
JP 2000-242707 A 20000810
WO 2000-JP5521 W 20000818
OTHER SOURCE(S): MARPAT 134:193427
GI



I

AB The title compds. represented by general formula (I; wherein A represents optionally substituted Ph, optionally substituted phenoxy or optionally substituted benzyloxy), pharmaceutically acceptable salts thereof and hydrates of the same are prepd. These compds. are capable of, as a ligand of human peroxisome proliferator-activated receptor (PPAR), enhancing the transcriptional activity of the receptor and showing effects of lowering blood sugar level and lowering lipid level. Thus, 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzoic acid, Et3N, and CH2Cl2 were mixed, treated with Et chlorocarbonate under ice-cooling, and stirred for 10 min under ice-cooling, followed by adding a soln. of 4-benzyloxybenzylamine in CH2Cl2, and the resulting mixt. was stirred at room temp. for 2 h to give 77% N-[(4-benzyloxyphenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide (II). II and I (A = PhO) enhanced the transcriptional activity of human PPAR.alpha. in CHO cells with EC50 of 0.44 and 0.24 .mu.M, resp.

IT **326925-77-3P 326925-78-4P 326925-79-5P 326925-80-8P 326925-81-9P 326925-82-0P 326925-83-1P 326925-84-2P 326925-85-3P 326925-86-4P 326925-87-5P 326925-88-6P 326925-89-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted benzylthiazolidinedione derivs. as agonists of human peroxisome proliferator-activated receptor and blood sugar and lipid-lowering agents)

RN 326925-77-3 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326925-78-4 CAPLUS
CN Benzamide, N-([1,1'-biphenyl]-4-ylmethyl)-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 326925-79-5 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 326925-80-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(2-methoxyphenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326925-81-9 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(3-methoxyphenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326925-82-0 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(4-methoxyphenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326925-83-1 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(3-methylphenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326925-84-2 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(4-methylphenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326925-85-3 CAPLUS
CN Benzamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 326925-86-4 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 326925-87-5 CAPLUS
CN Benzamide, N-[[4-[(4-chlorophenyl)methoxy]phenyl]methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 326925-88-6 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-[(4-

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS (Continued)
methylphenyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326925-89-7 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.79	145.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.62	-0.62

FILE 'REGISTRY' ENTERED AT 12:39:45 ON 23 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 21 AUG 2002 HIGHEST RN 444646-89-3
DICTIONARY FILE UPDATES: 21 AUG 2002 HIGHEST RN 444646-89-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10049904.str

L5 STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l5 full
FULL SEARCH INITIATED 12:41:00 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 211 TO ITERATE

100.0% PROCESSED 211 ITERATIONS 56 ANSWERS
SEARCH TIME: 00.00.01

L6 56 SEA SSS FUL L5

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	140.66	285.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.62

FILE 'CAPLUS' ENTERED AT 12:41:03 ON 23 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Aug 2002 VOL 137 ISS 8
FILE LAST UPDATED: 21 Aug 2002 (20020821/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l5
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 12:41:07 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS 2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 44 TO 476
PROJECTED ANSWERS: 2 TO 124

L7 2 SEA SSS SAM L5

L8 2 L7

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.40	287.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.62

FILE 'CAPLUS' ENTERED AT 12:41:19 ON 23 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Aug 2002 VOL 137 ISS 8
FILE LAST UPDATED: 21 Aug 2002 (20020821/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l5
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 12:41:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:	ONLINE	**COMPLETE**	
	BATCH	**COMPLETE**	
PROJECTED ITERATIONS:		44 TO	476
PROJECTED ANSWERS:		2 TO	124

L9 2 SEA SSS SAM L5

L10 2 L9

=>

=>

=>

=>

=>

=>

=>

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.40	288.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.62

FILE 'CAPLUS' ENTERED AT 12:41:34 ON 23 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

strictly prohibited.

FILE COVERS 1907 - 23 Aug 2002 VOL 137 ISS 8
FILE LAST UPDATED: 21 Aug 2002 (20020821/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l6
L11 33 L6

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.40	288.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.62

FILE 'REGISTRY' ENTERED AT 12:41:44 ON 23 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 21 AUG 2002 HIGHEST RN 444646-89-3
DICTIONARY FILE UPDATES: 21 AUG 2002 HIGHEST RN 444646-89-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d scan l6

L6 56 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-(phenylmethyl)- (9CI)
MF C19 H18 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 56 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]-, monopotassium salt (9CI)
MF C20 H17 F3 N2 O4 S . K



● K

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 56 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, N-[(3,4-dichlorophenyl)methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI)
MF C19 H16 Cl2 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 56 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(1-methylethoxy)phenyl]methyl]- (9CI)
MF C22 H24 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 56 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, N-[(4-chlorophenyl)methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI)
MF C19 H17 Cl N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 56 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]- (9CI)
MF C26 H24 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> s l6 not l3
L12          43 L6 NOT L3

=> d scan l12
```

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, N-(1,3-benzodioxol-5-ylmethyl)-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI)
MF C20 H18 N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):42

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4-nitrophenyl)methyl]- (9CI)
MF C19 H17 N3 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-(phenylmethyl)- (9CI)
MF C19 H18 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4-methoxyphenyl)methyl]- (9CI)
MF C20 H20 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C20 H17 F3 N2 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Glycine, N-[(4-bromo-2-fluorophenyl)methyl]-N-[3-[(2,4-dioxo-5-thiazolidinyl)methyl]benzoyl]- (9CI)
MF C20 H16 Br F N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI)
MF C20 H17 F3 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-hydroxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C19 H15 F3 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]-, monopotassium salt, monohydrate (9CI)
MF C20 H17 F3 N2 O4 S . H2 O . K



● K

● H_2O

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4-methylphenyl)methyl]- (9CI)
MF C20 H20 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C20 H17 F3 N2 O4 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]-, monopotassium salt (9CI)
MF C20 H17 F3 N2 O4 S . K



● K

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI)
MF C21 H16 F6 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 3-[(2,4-dioxo-5-thiazolidinyl)methyl]-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C19 H15 F3 N2 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]-, monosodium salt, monohydrate (9CI)
MF C20 H17 F3 N2 O4 S . H2 O . Na



● Na

● H_2O

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-fluoro-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C19 H14 F4 N2 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-methyl-N-(phenylmethyl)- (9CI)
MF C20 H20 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]-, monosodium salt (9CI)
MF C20 H17 F3 N2 O4 S . Na



● Na

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 3-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C20 H17 F3 N2 O4 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-N-ethyl-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C22 H21 F3 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, N-[(3,4-dichlorophenyl)methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI)
MF C19 H16 Cl2 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 3-[(2,4-dioxo-5-thiazolidinyl)methyl]-4-methoxy-N-(phenylmethyl)- (9CI)
MF C19 H18 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 3-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]-, compd. with (R)-.alpha.-methylbenzenemethanamine (1:1) (9CI)
MF C20 H17 F3 N2 O4 S . C8 H11 N

CM 1



CM 2

Absolute stereochemistry.

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, N-[(2,4-dichlorophenyl)methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI)
MF C19 H16 Cl2 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, N-(1,3-benzodioxol-5-ylmethyl)-3-[(2,4-dioxo-5-thiazolidinyl)methyl]-4-methoxy- (9CI)
MF C20 H18 N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 3-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]-, compd. with (S)-.alpha.-methylbenzenemethanamine (1:1) (9CI)
MF C20 H17 F3 N2 O4 S . C8 H11 N

CM 1



CM 2

Absolute stereochemistry.

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4-propoxyphenyl)methyl]- (9CI)
MF C22 H24 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 3-[(2,4-dioxo-5-thiazolidinyl)methyl]-4-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C20 H17 F3 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 3-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-hydroxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C19 H15 F3 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(1-methylethoxy)phenyl]methyl]- (9CI)
MF C22 H24 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-N-[(4-fluorophenyl)methyl]-2-methoxy- (9CI)
MF C19 H17 F N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-(1-methylethoxy)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C22 H21 F3 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-N-[(4-ethoxyphenyl)methyl]-2-methoxy- (9CI)
MF C21 H22 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, N-[(3,4-dimethoxyphenyl)methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI)
MF C21 H22 N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, N-(1,3-benzodioxol-5-ylmethyl)-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-ethoxy- (9CI)
MF C21 H20 N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI)
MF C20 H17 F3 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI)
MF C23 H26 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-ethoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C21 H19 F3 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, N-[(4-chlorophenyl)methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI)
MF C19 H17 Cl N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C20 H17 F3 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, N-[[4-(dimethylamino)phenyl]methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI)
MF C21 H23 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, N-[(4-bromophenyl)methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI)
MF C19 H17 Br N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 43 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C20 H17 F3 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.90	290.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.62

FILE 'CAPLUS' ENTERED AT 12:44:33 ON 23 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Aug 2002 VOL 137 ISS 8
FILE LAST UPDATED: 21 Aug 2002 (20020821/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l11 and PPAR
2658 PPAR
406 PPARS
2700 PPAR
(PPAR OR PPARS)
L13 17 L11 AND PPAR

=> d ibib abs hitstr 1-17

L13 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:575765 CAPLUS
TITLE: Benzopyrancarboxylic acid derivatives with **PPAR** agonist activity for the treatment of diabetes and lipid disorders, and their preparation, pharmaceutical compositions, and use
INVENTOR(S): Sahoo, Soumya P.; Koyama, Hiroo; Miller, Daniel J.; Boueres, Julia K.; Desai, Ranjit C.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002103242	A1	20020801	US 2001-21667	20011029
WO 2002060434	A2	20020808	WO 2001-US49501	20011026

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-244698P P 20001031
GI



I



II

AB A class of benzopyrancarboxylic acid derivs. is disclosed, which comprises compds. that are potent agonists (no data) of peroxisome proliferator activated receptors (**PPAR**) alpha and/or gamma, and are therefore useful in the treatment, control, or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other **PPAR** alpha and/or gamma mediated diseases, disorders and conditions. In particular, compds. I and their pharmaceutically acceptable salts and/or prodrugs are disclosed [wherein: Z = CH2, CO; R1 = H, OH, halo, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, or aryl; or R1 forms (un)substituted cyclopropane fusion to adjacent C atom; X, Y = O, S, SO, SO2, CH2, (un)substituted NH; n = 1-6; R4 = (un)substituted benzoheterocyclyl, cycloalkyl, heterocyclyl, cycloalkyloxy, halo, OH or derivs., alk(en/yn)yl, alk(en/yn)yloxy, or aryl, etc.; other R groups = H, halo, OH, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, aryl, aryloxy, aroyl, etc.; or R3R4 or R4R5 = (un)substituted 5- or 6-membered heterocyclic ring]. A list of 29 compds. is claimed, and their prepn. is described. For example, Et 7-hydroxy-4-oxo-4H-chromene-2-carboxylate underwent a sequence of: (1) complete hydrogenation of the enone (98%), (2) etherification of the alc. with PhCH2O(CH2)3Br (66%), (3) alpha ethylation of the ester (70%), (4) hydrogenolytic debenzylation (100%), (5) conversion of the resultant alc. to a bromide (96%), (6) etherification of the bromide with 3-(trifluoromethyl)-7-propyl-6-hydroxybenz[4,5]isoxazole (85%), and (7) alk. hydrolysis (100%), to give title compd. II. **PPAR** binding assays using human recombinant **PPAR** are described without data. Co-administration of compds. I with a variety of other drug categories, including a no. of specific drugs, is claimed.

IT **213252-19-8**, KRP-297
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. also contg.; prepn. of benzopyrancarboxylic acid derivs. as **PPAR** agonists for treatment of diabetes and lipid disorders)

RN 213252-19-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:409256 CAPLUS
DOCUMENT NUMBER: 137:735
TITLE: Methods and compositions for treatment of diabetes and related conditions via gene therapy
INVENTOR(S): Caplan, Shari L.; Boettcher, Brian R.; Slosberg, Eric D.; Connelly, Sheila; Kaleko, Michael; Desai, Urvi J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002065239	A1	20020530	US 2001-808457	20010314

PRIORITY APPLN. INFO.: US 2000-266328P P 20000315

AB Methods and compns. are disclosed for the treatment of diabetes, obesity and diabetic-related conditions. The methods include gene therapy based administration of a therapeutically effective amt. of vectors encoding the following: glucokinase regulatory protein alone or co-administered with glucokinase or with metab. modifying proteins; glucokinase co-administered with metab. modifying proteins; or glucokinase regulatory protein co-administered with glucokinase in combination with metab. modifying proteins, to a diabetic patient. The metab. modifying proteins include UCP2, UCP3, **PPAR**.alpha., OB-Rb, GLP-1 and GLP-1 analogs (administered via vector or directly as a peptide). Preferred examples of GLP-1 analogs include GLP-1-Gly8, Extendin-4 and the "Black Widow" chimeric GLP-1 analog. Addnl., **PPAR**.alpha. ligands and DPP-IV inhibitors may be co-administered with the above.

IT **213252-19-8**, KRP-297
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gene therapy for treatment of diabetes and related conditions)

RN 213252-19-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:142553 CAPLUS
DOCUMENT NUMBER: 136:177969
TITLE: Medicinal compositions containing **PPAR** .gamma. agonists and RXR agonists for preventing and treating cancer
INVENTOR(S): Kurakata, Shinichi; Fujiwara, Kosaku; Shimazaki, Naomi; Fujita, Takashi
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013864	A1	20020221	WO 2001-JP7037	20010815

W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, SG, SK, US, ZA
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

JP 2002128700	A2	20020509	JP 2001-241740	20010809
AU 2001078738	A5	20020225	AU 2001-78738	20010815

PRIORITY APPLN. INFO.: JP 2000-246910 A 20000816
JP 2000-2000246910A 20000816
WO 2001-JP7037 W 20010815

OTHER SOURCE(S): MARPAT 136:177969

AB Disclosed are medicinal compns. for preventing or treating cancer wherein one or more Peroxisome proliferator-activated receptor .gamma. (**PPAR**.gamma.) activation agonists and one or more retinoid X receptor (RXR) activation agonists are used simultaneously or successively. A combined administration of 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione hydrochloride (I) 5 and targretin 100 mg/kg to HL-60 cell-bearing mice showed synergistic antitumor effect. Also, tablets were prepd. from I 0.004, targretin 0.1, lactose 0.244, corn starch 50, and magnesium stearate 0.002 g.

IT **213252-19-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(simultaneous or successive use of **PPAR**.gamma. agonists and RXR agonists for prevention or treatment of cancer)

RN 213252-19-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:142506 CAPLUS
DOCUMENT NUMBER: 136:177977
TITLE: Methods for treating inflammatory diseases using **PPAR** agonists
INVENTOR(S): Pershadsingh, Harrihar A.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013812	A1	20020221	WO 2001-US25668	20010816
W: AU, CA, MX, NZ, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001088271	A5	20020225	AU 2001-88271	20010816

PRIORITY APPLN. INFO.: US 2000-225907P P 20000817
US 2000-230509P P 20000906
WO 2001-US25668 W 20010816

AB The present invention describes methods for the use of **PPAR** ligands in the treatment inflammatory endocrine, dermatol., cardiovascular immunol., neurol., ophthalmic, neoplastic, pulmonary diseases, and age-related dysregulations. In addn., methods are provided for treating said conditions and diseases comprising the step of administering to a human or an animal in need thereof a therapeutic amt. of pharmacol. compns. comprising a pharmaceutically acceptable carrier, and a **PPAR**.gamma. agonist which cross-activates **PPAR**.alpha. or **PPAR**.delta. or both, or a **PPAR**.gamma. partial agonist, or a **PPAR**.gamma./RXR agonist, effective to reverse, slow, stop, or prevent the pathol. inflammatory or degenerative process.

IT **213252-19-8**, KRP 297
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for treating inflammatory diseases using **PPAR** agonists)

RN 213252-19-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:90008 CAPLUS
DOCUMENT NUMBER: 136:151071
TITLE: Preparation of N-substituted indoles for treating diabetes
INVENTOR(S): Acton, John J., III; Black, Regina Marie; Jones, Anthony Brian; Wood, Harold Blair
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008188	A1	20020131	WO 2001-US22979	20010720
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002042441	A1	20020411	US 2001-912961	20010725

PRIORITY APPLN. INFO.: US 2000-220778P P 20000725
OTHER SOURCE(S): MARPAT 136:151071
GI



I



II

L13 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

AB The title indoles having aryloxyacetic acid substituents [I; R1 = Me, optionally substituted with 1-3 F atoms; R2-R4 = H, halo, alkyl, etc.; R5, R6 = H, F, OH, alkyl; and R5 and R6 groups that are on the same carbon atom optionally may be joined to form a cyclopropyl group; R7, R8 = H, F, alkyl; or CR7R8 may form cycloalkyl; R9 = H, alkyl; Ar1 = (un)substituted Ph, naphthyl, pyridyl, quinolyl; X = CO, SO2, CH2, CHMe, CMe2, CF2, cyclopropylidene; Y = O, S; n = 0-5] which are agonists or partial agonists of **PPAR** gamma, and are useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other **PPAR** mediated diseases, disorders and conditions, were prepd. E.g., a multi-step synthesis of (2S)-II was given.

IT **213252-19-8**, KRP-297
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of N-substituted indoles for treating diabetes)

RN 213252-19-8 CAPLUS

CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:56491 CAPLUS
DOCUMENT NUMBER: 137:73203
TITLE: Pharmacological analysis of wild-type .alpha., .gamma. and .delta. subtypes of the human peroxisome proliferator-activated receptor
AUTHOR(S): Wurch, T.; Junquero, D.; Delhon, A.; Pauwels, P. J.
CORPORATE SOURCE: Department of Cellular and Molecular Biology, Centre de Recherche Pierre Fabre, Castres, 81106, Fr.
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (2002), 365(2), 133-140
CODEN: NSAPCC; ISSN: 0028-1298
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Three distinct peroxisome proliferator-activated receptor (**PPAR**) cDNAs were isolated from human brain RNA. Whereas the **PPAR** .delta. subtype perfectly matched the amino acid sequences reported in the Genbank database, several differences were found for the **PPAR** .alpha. (Lys123Met, Ala268Val, Gly296Ala and Val444Ala) and **PPAR** .gamma.2 (Met8Ile, Pro9Ala, Met186Ile, Pro187Ala and the deletion of a Gln213 residue) subtypes. A pharmacol. anal. was undertaken by co-expressing each **PPAR** subtype with a reporter plasmid contg. a luciferase gene under the transcriptional control of a synthetic, triplicated **PPAR** response element in either HepG2 or Cos-7 cells. Whereas fenofibrate unselectively activated the **PPAR** .alpha. and **PPAR**.delta. subtypes, the related BM-17.0744 compd. was more potent and selective for **PPAR**.alpha.. The thiazolidine dione derivs. rosiglitazone and pioglitazone were potent and selective **PPAR**.gamma.2 agonists. L-165041, reported as a selective and potent **PPAR**.delta. ligand, displayed in this specified transactivation system, apart from its highly efficacious **PPAR** .delta. agonist activity, partial and full agonism at, resp., **PPAR** .alpha. and **PPAR**.gamma.2 subtypes. In conclusion, transcriptional control of a luciferase gene by wild-type **PPAR** subtypes provides powerful recombinant assays to evaluate ligand's efficacy at these nuclear receptors.

IT **213252-19-8**, KRP-297
RL: PAC (Pharmacological activity); BIOL (Biological study)
(pharmacol. anal. of wild-type .alpha., .gamma. and .delta. subtypes of human peroxisome proliferator-activated receptor)

RN 213252-19-8 CAPLUS

CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:900080 CAPLUS
DOCUMENT NUMBER: 136:318816
TITLE: Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (**PPAR**) activators: novel human **PPAR** .alpha.-selective activators
AUTHOR(S): Miyachi, Hiroyuki; Nomura, Masahiro; Tanase, Takahiro; Takahashi, Yukie; Ide, Tomohiro; Tsunoda, Masaki; Murakami, Koji; Awano, Katsuya
CORPORATE SOURCE: Kyorin Pharmaceutical Co., Ltd., Discovery Research Laboratories, Tochigi, Shimotsuga-gun, Nogi-machi, 329-0114, Japan
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), Volume Date 2002, 12(1), 77-80
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of substituted phenylpropanoic acid derivs. was prepd. as part of a search for subtype-selective human peroxisome proliferator-activated receptor (**PPAR**) activators. Structure-activity relationship studies indicated that the substituent at the .alpha.-position of the carboxyl group plays a key role in detg. the potency and the selectivity for **PPAR** transactivation.

IT **213252-19-8**, KRP 297
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(design, synthesis and evaluation of substituted phenylpropanoic acid derivs. as **PPAR** activators)

RN 213252-19-8 CAPLUS

CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:617987 CAPLUS
DOCUMENT NUMBER: 135:180757
TITLE: Preparation of 1,2-benzoxazolyloxyacetic acids and analogs as **PPAR** agonists for treatment of diabetes and lipid disorders
INVENTOR(S): Liu, Kun; Xu, Libo; Jones, A. Brian
PATENT ASSIGNEE(S): Merck + Co. Inc., USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060807	A1	20010823	WO 2001-US4636	20010214

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-183593P P 20000218
OTHER SOURCE(S): MARPAT 135:180757
GI


I


II

AB The title compds. (I) [wherein R1 and R2 = independently H, F, (halo)alkyl, (halo)alkenyl, (halo)alkynyl; or R1 and R2 may form a cycloalkyl group; R3 and R4 = independently (fluoro)alkyl, (fluoro)alkenyl, (fluoro)alkynyl, or Cl; X = N or CR; Y = O, S, nor NR; Z = O or S; R = independently H or optionally fluoro- or alkoxy-substituted (cyclo)alkyl(oxy), alkenyl(oxy), or alkynyl(oxy); R5 = H or (un)substituted alkyl, alkenyl, alkynyl, (hetero)aryl(oxy), heterocyclyl(oxy), etc.; and pharmaceutically acceptable salts and

L13 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)
prodrugs thereof] were prepd. For example, 2,4-dihydroxy-3,5-dipropyl-1',1',1'-trifluoroacetophenone oxime was acetylated and then treated with pyridine and TEA to give 5,7-dipropyl-6-hydroxy-3-trifluoromethyl-1,2-benzisoxazole. Etherification with Me .alpha.-bromoisobutyrate in the presence of Cs2CO3 in DMF, followed by sapon., afforded the 1,2-benzoxazolyloxyacetic acid (II). I are potent agonists of peroxisome proliferator activated receptor (**PPAR**) .alpha. and/or .gamma. and are useful in the treatment, control, or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other **PPAR**.alpha. and/or .gamma. mediated diseases, disorders, and conditions (no data).
IT **213252-19-8**, KRP-297
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration with; prepn. of benzisoxazolyloxyacetic acid **PPAR** agonists via cyclization of dihydroxyacetophenone oximes for treatment of diabetes and lipid disorders)
RN 213252-19-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:617810 CAPLUS
DOCUMENT NUMBER: 135:175429
TITLE: Modulation of bone formation with peroxisome proliferator-activated receptor activators and ligands
INVENTOR(S): Scutt, Andrew; Still, Karen
PATENT ASSIGNEE(S): University of Sheffield, UK
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060355	A1	20010823	WO 2001-GB626	20010215

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2000-3310 A 20000215
AB The use of an activator or ligand of a peroxisome proliferator-activated receptor, other than **PPAR**.gamma., or pharmaceutically acceptable deriv. of said activator or ligand, in the manuf. of a medicament for the treatment or prophylaxis of bone disease allows, for the first time, bone anabolism to enhance the deposition of bone in conditions which would benefit from increased bone deposition. The reverse, where there is inhibition and/or retardation of bone deposition is also facilitated.
IT **213252-19-8**, KRP-297
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulation of bone formation with peroxisome proliferator-activated receptor activators and ligands)
RN 213252-19-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS

L13 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:367156 CAPLUS
DOCUMENT NUMBER: 135:131731
TITLE: Design and Synthesis of 2-Methyl-2-{4-[2-(5-methyl-2-aryloxazol- 4-yl)ethoxy]phenoxy)propionic Acids: A New Class of Dual **PPAR**.alpha./.gamma. Agonists
AUTHOR(S): Brooks, Dawn A.; Etgen, Garret J.; Rito, Christopher J.; Shuker, Anthony J.; Dominianni, Samuel J.; Warshawsky, Alan M.; Ardecky, Robert; Paterniti, James R.; Tyhonas, John; Karanewsky, Donald S.; Kauffman, Raymond F.; Broderick, Carol L.; Oldham, Brian A.; Montrose-Rafizadeh, Chahzrad; Winneroski, Leonard L.; Faul, Margaret M.; McCarthy, James R.
CORPORATE SOURCE: Lilly Research Laboratories A Division of Eli Lilly Company Lilly Corporate Center, Indianapolis, IN, 46285, USA
SOURCE: Journal of Medicinal Chemistry (2001), 44(13), 2061-2064
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Propionic acid deriv. I, which was designed and synthesized based on putative pharmacophores of known **PPAR**.gamma.- and **PPAR** .alpha.-selective compds., exhibits potent dual **PPAR** .alpha./.gamma. agonist activity as demonstrated by in vitro binding and dose overlap in the newly introduced EOB mouse model for glucose lowering and lipid/cholesterol homeostasis.
IT **213252-19-8**, KRP-297
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy)propionic acids: a new class of dual **PPAR** .alpha./.gamma. agonists)
RN 213252-19-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:359797 CAPLUS
DOCUMENT NUMBER: 134:344620
TITLE: Solid oral composition containing KRP-297
INVENTOR(S): Ohyama, Toshinori; Imamizu, Masaru
PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001034148	A1	20010517	WO 2000-JP7905	20001110

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 1999-320586 A 19991111
AB Disclosed are solid compns. for oral use for facilitating the administration in a small dose of KRP-297, which is a ligand common to peroxisome proliferator-activated receptors **PPAR**.alpha. and **PPAR**.gamma. (i.e., nuclear receptors) and has an effect of ameliorating insulin resistance, which contain the drug ingredient in a uniform content and can be easily and quant. taken. By prepg. solid compns. for oral use composed of a trace amt. of the drug ingredient together with pharmaceutical carriers, it is possible to provide tablets which contain the drug component in a uniform content and can be easily and quant. taken. A film-coated tablet was prepd. from KRP-297 0.25, lactose 78.55, cryst. cellulose 26.2, low-substituted hydroxypropyl cellulose 12, polyvinyl alc. 2.4, magnesium stearate 0.6, hydroxypropyl Me cellulose, and carnauba wax 0.001 mg.
IT **213252-19-8**, KRP-297
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid oral compns. contg. uniform contents of KRP-297)
RN 213252-19-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:152661 CAPLUS
DOCUMENT NUMBER: 134:193428
TITLE: Preparation of substituted benzylthiazolidine-2,4-dione derivatives as agonists of human peroxisome proliferator-activated receptor
INVENTOR(S): Nomura, Masahiro; Murakami, Koji; Tsunoda, Masaki; Takahashi, Yukie
PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014352	A1	20010301	WO 2000-JP5522	20000818
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1207158	A1	20020522	EP 2000-953478	20000818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: JP 1999-235530 A 19990823
WO 2000-JP5522 W 20000818
OTHER SOURCE(S): MARPAT 134:193428
GI



I

AB The title compds. (I), pharmaceutically acceptable salts thereof and hydrates of the same (wherein R1 represents chloro, bromo, nitro, trifluoromethoxy, ethoxy, propoxy or isopropoxy; and R2 represents hydrogen or chloro) are prepd. These compds. are capable of, as a ligand of human peroxisome proliferator-activated receptor (**PPAR**), enhancing the transcriptional activity of the receptor and showing effects of lowering blood sugar level and lowering lipid level; and a process for producing the same. Thus, 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzoic acid, Et3N, and CH2Cl2 were mixed, treated with Et chlorocarbonate and stirred under ice-cooling for 10 min, treated with 4-nitrobenzylamine, and then stirred at room temp. for 2 h to give 75% N-[(4-nitrophenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide (II). II and I (R1 = 4-n-Pro, R2 = H) enhanced the transcriptional activity of human **PPAR**.alpha. in CHO cells with EC50 of 0.53 and 0.11 .mu.M, resp.

IT **326926-46-9P 326926-47-0P 326926-48-1P**
326926-49-2P 326926-50-5P 326926-51-6P
326926-52-7P 326926-53-8P 326926-54-9P,
N-[(3,4-Dichlorophenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted benzylthiazolidinedione derivs. as agonists of human peroxisome proliferator-activated receptor and blood sugar and lipid-lowering agents)

RN 326926-46-9 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 326926-47-0 CAPLUS
CN Benzamide, N-[(4-bromophenyl)methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)

L13 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 326926-48-1 CAPLUS
CN Benzamide, N-[(4-chlorophenyl)methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 326926-49-2 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326926-50-5 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-N-[(4-ethoxyphenyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)

L13 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 326926-51-6 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(1-methylethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326926-52-7 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4-propoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 326926-53-8 CAPLUS
CN Benzamide, N-[(2,4-dichlorophenyl)methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)

L13 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 326926-54-9 CAPLUS
CN Benzamide, N-[(3,4-dichlorophenyl)methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:152660 CAPLUS
DOCUMENT NUMBER: 134:193427
TITLE: Preparation of substituted benzylthiazolidine-2,4-dione derivatives as agonists of human peroxisome proliferator-activated receptor
INVENTOR(S): Miyachi, Hiroyuki; Nomura, Masahiro; Tanase, Takahiro; Murakami, Koji; Tsunoda, Masaki
PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014351	A1	20010301	WO 2000-JP5521	20000818
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1207157	A1	20020522	EP 2000-953477	20000818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: JP 1999-235529 A 19990823
JP 2000-242707 A 20000810
WO 2000-JP5521 W 20000818
OTHER SOURCE(S): MARPAT 134:193427
GI



AB The title compds. represented by general formula (I; wherein A represents optionally substituted Ph, optionally substituted phenoxy or optionally substituted benzyloxy), pharmaceutically acceptable salts thereof and hydrates of the same are prepd. These compds. are capable of, as a ligand of human peroxisome proliferator-activated receptor (**PPAR**), enhancing the transcriptional activity of the receptor and showing effects of lowering blood sugar level and lowering lipid level. Thus,

L13 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)
5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzoic acid, Et3N, and CH2Cl2 were mixed, treated with Et chlorocarbonate under ice-cooling, and stirred for 10 min under ice-cooling, followed by adding a soln. of 4-benzyloxybenzylamine in CH2Cl2, and the resulting mixt. was stirred at room temp. for 2 h to give 77% N-[(4-benzyloxyphenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide (II). II and I (A = PhO) enhanced the transcriptional activity of human **PPAR**.alpha. in CHO cells with EC50 of 0.44 and 0.24 .mu.M, resp.

IT **326925-77-3P 326925-78-4P 326925-79-5P 326925-80-8P 326925-81-9P 326925-82-0P 326925-83-1P 326925-84-2P 326925-85-3P 326925-86-4P 326925-87-5P 326925-88-6P 326925-89-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted benzylthiazolidinedione derivs. as agonists of human peroxisome proliferator-activated receptor and blood sugar and lipid-lowering agents)

RN 326925-77-3 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326925-78-4 CAPLUS
CN Benzamide, N-([1,1'-biphenyl]-4-ylmethyl)-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 326925-79-5 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4-

L13 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)
phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 326925-80-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(2-methoxyphenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326925-81-9 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(3-methoxyphenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326925-82-0 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(4-methoxyphenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 326925-83-1 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(3-methylphenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326925-84-2 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(4-methylphenoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326925-85-3 CAPLUS
CN Benzamide, N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-5-[(2,4-dioxo-5-

L13 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)
RN 326925-88-6 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-[(4-methylphenyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326925-89-7 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)
thiazolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 326925-86-4 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[(4'-methoxy[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 326925-87-5 CAPLUS
CN Benzamide, N-[[4-[(4-chlorophenyl)methoxy]phenyl]methyl]-5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



L13 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:293502 CAPLUS
DOCUMENT NUMBER: 133:84110
TITLE: Fenofibrate and Rosiglitazone Lower Serum Triglycerides with Opposing Effects on Body Weight
AUTHOR(S): Chaput, Evelyne; Saladin, Regis; Silvestre, Martine; Edgar, Alan D.
CORPORATE SOURCE: Department of Metabolic Diseases, Laboratoire Fournier, Daix, 21121, Fr.
SOURCE: Biochemical and Biophysical Research Communications (2000), 271(2), 445-450
CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Activators of peroxisome proliferator activated receptors (**PPARs**) are effective drugs to improve the metabolic abnormalities linking hypertriglyceridemia to diabetes, hyperglycemia, insulin-resistance, and atherosclerosis. We compared the pharmacol. profile of a **PPAR**.alpha. activator, fenofibrate, and a **PPAR**.gamma. activator, rosiglitazone, on serum parameters, target gene expression, and body wt. gain in (fa/fa) fatty Zucker rats and db/db mice as well as their assocn. in db/db mice. Fenofibrate faithfully modified the expression of **PPAR**.alpha. responsive genes. Rosiglitazone increased adipose tissue aP2 mRNA in both models while increasing liver acyl CoA oxidase mRNA in db/db mice but not in fatty Zucker rats. Both drugs lowered serum triglycerides yet rosiglitazone markedly increased body wt. gain while fenofibrate decreased body wt. gain in fatty Zucker rats. KRP 297, which has been reported to be a **PPAR**.alpha. and .gamma. co-activator, also affected serum triglycerides and insulin in fatty Zucker rats although no change in body wt. gain was noted. These results serve to clearly differentiate the metabolic finality of two distinct classes of drugs, as well as their corresponding nuclear receptors, having similar effects on serum triglycerides. (c) 2000 Academic Press.

IT **213252-19-8**, KRP 297
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body wt.)

RN 213252-19-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

L13 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:436161 CAPLUS
DOCUMENT NUMBER: 131:238315
TITLE: Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferator-activated receptor .alpha.
AUTHOR(S): Murakami, Koji; Ide, Tomohiro; Suzuki, Masahiro; Mochizuki, Toshiro; Kadowaki, Takashi
CORPORATE SOURCE: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan
SOURCE: Biochemical and Biophysical Research Communications (1999), 260(3), 609-613
CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The .alpha. isoform of peroxisome proliferator-activated receptor (**PPAR**) is activated by fatty acids, their metabolites, and the fibrate class of lipid-lowering agents. To test the ability of these activators to directly bind the ligand-binding domain of human **PPAR**.alpha., we performed a competitive binding assay using radiolabeled [3H]KRP-297, a known ligand for human **PPAR**.alpha.. Long-chain fatty acids and eicosanoids were even more potent ligands for human **PPAR**.alpha. than the hitherto most potent **PPAR** .alpha. ligand WY-14,643. Moreover, these natural ligands avidly activated this receptor in a transient transcriptional assay. This study provides the direct evidence that human **PPAR**.alpha. is activated through the direct binding of fatty acids and eicosanoids, as well as of a fibrate, to its ligand-binding domain. (c) 1999 Academic Press.
IT **213252-19-8**, KRP-297
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(direct binding of fatty acids and eicosanoids to human peroxisome proliferator-activated receptor .alpha.)
RN 213252-19-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

L13 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:784882 CAPLUS
DOCUMENT NUMBER: 130:148506
TITLE: A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-.alpha. (**PPAR**-.alpha.) and **PPAR**-.gamma.: effect of **PPAR**-.alpha. activation on abnormal lipid metabolism in liver of Zucker fatty rats
AUTHOR(S): Murakami, Koji; Tobe, Kazuyuki; Ide, Tomohiro; Mochizuki, Toshiro; Ohashi, Mitsuo; Akanuma, Yasuo; Yazaki, Yoshio; Kadowaki, Takashi
CORPORATE SOURCE: Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Tokyo, 113, Japan
SOURCE: Diabetes (1998), 47(12), 1841-1847
CODEN: DIAEAZ; ISSN: 0012-1797
PUBLISHER: American Diabetes Association
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We investigated the biol. activity of a novel thiazolidinedione (TZD) deriv., KRP-297, and the mol. basis of this activity. When administered to obese Zucker fatty rats (obese rats) at 10 mg/kg for 2 wk, KRP-297, unlike BRL-49653, restored reduced lipid oxidn., i.e., CO2 and ketone body prodn. from [14C]palmitic acid, in the liver by 39% ($P < 0.05$) and 57% ($P < 0.01$), resp. KRP-297 was also significantly more effective than BRL-49653 in the inhibition of enhanced lipogenesis and triglyceride accumulation in the liver. To understand the mol. basis of the biol. effects of KRP-297, we examd. the effect on peroxisome proliferator-activated receptor (**PPAR**) isoforms, which may play key roles in lipid metab. Unlike classical TZD derivs., KRP-297 activated both **PPAR**-.alpha. and **PPAR**-.gamma., with median effective concns. of 1.0 and 0.8 .mu.mol/L, resp. Moreover, radiolabeled [3H]KRP-297 bound directly to **PPAR**-.alpha. and **PPAR** -.gamma. with dissocn. consts. of 228 and 326 nmol/L, resp. Concomitantly, KRP-297, but not BRL-49653, increased the mRNA and the activity (1.5-fold [$P < 0.01$] and 1.8-fold [$P < 0.05$], resp.) of acyl-CoA oxidase, which has been reported to be regulated by **PPAR** -.alpha., in the liver. By contrast, KRP-297 ($P < 0.05$) was less potent than BRL-49653 ($P < 0.01$) in inducing the **PPAR**-.gamma.-regulated aP2 gene mRNA expression in the adipose tissues. These results suggest that **PPAR**-.alpha. agonism has a protective effect against abnormal lipid metab. in liver of obese rats.
IT **213252-19-8**, KRP 297
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of **PPAR**-.alpha. activation by insulin sensitizer, thiazolidinedione deriv. KRP-297, on abnormal lipid metab. in liver of Zucker fatty rats)
RN 213252-19-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:421607 CAPLUS
DOCUMENT NUMBER: 129:239719
TITLE: Effects of **PPAR**.alpha. activation on liver lipid metabolism in Zucker fatty rats
AUTHOR(S): Ide, Tomohiro; Murakami, Koji; Tobe, Kazuyuki; Mochizuki, Toshiro; Ohashi, Mitsuo; Akanuma, Yasuo; Kadowaki, Takashi; Yazaki, Yoshio
CORPORATE SOURCE: Cent. Res. Lab., Kyorin Pharm. Co., Ltd., Tochigi, 329-01, Japan
SOURCE: Diabetes Frontier (1998), 9(3), 345-346
CODEN: DIFREZ; ISSN: 0915-6593
PUBLISHER: Medikaru Rebyusha
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB Oral administration of KRP-297 or BRL-49653 with high affinity to **PPAR** .alpha. to Zucker fatty (obese) rats and to control lean rats for 2 wk significantly lowered the blood glucose, insulin, triglyceride, and free fatty acid levels in the obese rats. KRP-297 and BRL-49653 also suppressed the increase in triglyceride accumulation and fatty acid biosynthesis activity in the liver of the obese rats as compared to the lean rats. In contrast, the markedly reduced activity of the hepatic acyl-CoA oxidase in the obese rats was markedly recovered by the administration. The results suggest that the activation of **PPAR** .alpha. by KRP-297 or BRL-49653 (ligand) might have inhibitory action on the hepatic triglyceride accumulation and lipid metab. abnormality in the obese rats.

IT **213252-19-8**, KRP 297
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(effects of **PPAR**.alpha. activation on liver lipid metab. in Zucker fatty rats)

RN 213252-19-8 CAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	77.43	368.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.53	-11.15

STN INTERNATIONAL LOGOFF AT 12:46:29 ON 23 AUG 2002